Targets › RBM39
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.
RNA-binding protein that acts as a pre-mRNA splicing factor. Acts by promoting exon inclusion via regulation of exon cassette splicing. (UniProt, Q14498)
Open in Phaseline: the race on RBM39, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| SEED Therapeutics | ST-01156 RBM39 degrader | RBM39 | Phase 1 | Advanced Solid Tumors | Dec 2029 |
Advanced Solid Tumors (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.